The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations
Open accessAbstract
Cardiovascular disease remains the principal cause of death and disability among patients with diabetes mellitus. Diabetes mellitus exacerbates mechanisms underlying atherosclerosis and heart failure. Unfortunately, these mechanisms are not adequately modulated by therapeutic strategies focusing solely on optimal glycemic control with currently available drugs or approaches. In the setting of multifactorial risk reduction with statins and other lipid-lowering agents, antihypertensive therapies, and antihyperglycemic treatment strategies, cardiovascular complication rates are falling, yet remain higher for patients with diabetes mellitus than for those without. This review considers the mechanisms, history, controversies, new pharmacological agents, and recent evidence for current guidelines for cardiovascular management in the patient with diabetes mellitus to support evidence-based care in the patient with diabetes mellitus and heart disease outside of the acute care setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Lifestyle modification should be encouraged to lower cardiovascular risk and that for developing diabetes mellitus.(205) Patients on statins at higher risk for but without preexisting type 2 diabetes mellitus should undergo periodic screening for diabetes mellitus with fasting glucose and HbA 1c , and if type 2 diabet…”
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Cited by
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
Metabolic Effects of Dietary Nitrate in Health and Disease
Lundberg, J. O., Carlström, M., & Weitzberg, E. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.007 · Cited by 374
Type 2 diabetes mellitus and cardiovascular disease: Genetic and epigenetic links
De Rosa, S., Arcidiacono, B., Chiefari, E., Brunetti, A., Indolfi, C., & Foti, D. P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00002 · Cited by 369
Fisher, D. P., Johnson, E., Haneuse, S., Arterburn, D., Coleman, K. J., O’Connor, P. J., O’Brien, R., Bogart, A., Theis, M. K., Anau, J., et al. (2018) · JAMA · doi:10.1001/jama.2018.14619 · Cited by 305
Metabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies
Jin, Q., & Ma, R. C. W. (2021) · Cells · doi:10.3390/cells10112832 · Cited by 252
Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118825376 · Cited by 223
Ikonomidis, I., Pavlidis, G., Thymis, J., Birba, D., Kalogeris, A., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015716 · Cited by 199
Primary Prevention of Cardiovascular Disease in Diabetes Mellitus
Newman, J. D., Schwartzbard, A. Z., Weintraub, H. S., Goldberg, I. J., & Berger, J. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.001 · Cited by 205
Song, Y., Zhao, Y., Shu, Y., Zhang, L., Cheng, W., Wang, L., Shu, M., Xue, B., Wang, R., Feng, Z., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1100453 · Cited by 141
Mohammedi, K., Woodward, M., Marre, M., Colagiuri, S., Cooper, M., Harrap, S., Mancia, G., Poulter, N., Williams, B., Zoungas, S., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0574-y · Cited by 111
Cardiovascular Protective Effects of Centella asiatica and Its Triterpenes: A Review
Razali, N. N. M., Ng, C. T., & Fong, L. Y. (2019) · Planta Medica · doi:10.1055/a-1008-6138 · Cited by 95
Coopmans, C., Zhou, T. L., Henry, R. M. A., Heijman, J., Schaper, N. C., Koster, A., Schram, M. T., van der Kallen, C. J. H., Wesselius, A., den Engelsman, R. J. A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2367 · Cited by 93
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.015 · Cited by 83
Joubert, M., Manrique, A., Cariou, B., & Prieur, X. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.003 · Cited by 81
Al-Salameh, A., Chanson, P., Bucher, S., Ringa, V., & Becquemont, L. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.007 · Cited by 77
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
Jarolim, P., White, W. B., Cannon, C. P., Gao, Q., & Morrow, D. A. (2018) · Diabetes Care · doi:10.2337/dc18-0109 · Cited by 56
Cersosimo, E., Johnson, E. L., Chovanes, C., & Skolnik, N. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13108 · Cited by 52
Habibi, N., Mousa, A., Tay, C. T., Khomami, M. B., Patten, R. K., Andraweera, P. H., Wassie, M., Vandersluys, J., Aflatounian, A., Bianco‐Miotto, T., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3532 · Cited by 53
Makam, A. N., & Nguyen, O. K. (2017) · Circulation · doi:10.1161/circulationaha.116.022622 · Cited by 52
Palella, E., Cimino, R., Pullano, S. A., Fiorillo, A. S., Gulletta, E., Brunetti, A., Foti, D. P., & Greco, M. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17010300 · Cited by 48
Bi, C., Fu, Y., & Li, B. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109569 · Cited by 46
Kaze, A. D., Santhanam, P., Erqou, S., Ahima, R. S., & Echouffo-Tcheugui, J. B. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001753 · Cited by 40
Witte, K. K., Drozd, M., Walker, A. M. N., Patel, P. A., Kearney, J. C., Chapman, S., Sapsford, R. J., Gierula, J., Paton, M. F., Lowry, J., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1406 · Cited by 36
Yang, R., Xu, H., Pedersen, N. L., Li, X., Yu, J., Bao, C., Qi, X., & Xu, W. (2021) · Diabetologia · doi:10.1007/s00125-020-05324-z · Cited by 28
Wargny, M., Croyal, M., Ragot, S., Gand, E., Jacobi, D., Trochu, J.-N., Prieur, X., Le May, C., Goronflot, T., Cariou, B., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01505-9 · Cited by 21
Safety of injectable semaglutide for type 2 diabetes
Peter, R., & Bain, S. C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1772230 · Cited by 17
Masson, W., Lobo, M., Barbagelata, L., Lavalle-Cobo, A., & Molinero, G. (2021) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.06.001 · Cited by 17
Metadata
- Authors
- Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B.
- Venue
- Circulation
- Published
- 2016-06-14
- Volume
- 133
- Issue
- 24
- Pages
- 2459-2502
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2444268874
- Cited by
- 1,155
- References
- 148
- FWCI
- 70.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
